Skip to content

Study · In silico · 2026

6 results

Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.

Johansson E, Wilding JPH, Upadhyay N, van Hest N, Kirk M, Spaepen E, Zimner-Rapuch S, Annemans L, Bays H

Journal of medical economics21 Apr 2026

PMID42012820 (opens in a new tab)DOI10.1080/13696998.2026.2646078 (opens in a new tab)PepBankPUB-42012820
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01Computer modelIn silicoOther

    In a US simulation of adults with obesity or overweight, tirzepatide was estimated to be less costly than semaglutide, with per patient cost savings of $41,688.

    In plain wordsIn a computer simulation for obesity treatment, tirzepatide was estimated to cost less than semaglutide.

    Peptide
    Tirzepatide
    Outcome
    DecreasePer-patient cost savings vs semaglutide
    Study

    n: not reported in source

    Patient-level simulation model
    Comparator
    Semaglutide
    Outcome group
    Cost-effectiveness · Whole body
    Studied dose
    Maximum tolerated doseAs given in this study.

    Source sentences

    Summary
    Tirzepatide (MTD) was estimated to be less costly and more efficacious compared to semaglutide (MTD) with per patient cost savings of $41,688, 0.506 QALYs gained and positive iNHB of 0.784, indicating a net health benefit for tirzepatide.
    1 context sentence
    Summary · context
    This patient-level simulation modeling study assessed the cost and long-term clinical outcomes of tirzepatide (MTD) versus semaglutide (MTD), using data from the SURMOUNT-5 trial population.
  2. 02Computer modelIn silicoEfficacy outcome

    In a US simulation of adults with obesity or overweight, tirzepatide was estimated to gain 0.506 QALYs more than semaglutide.

    In plain wordsIn a computer simulation for obesity treatment, tirzepatide was estimated to give more healthy life years than semaglutide.

    Peptide
    Tirzepatide
    Outcome
    IncreaseQuality-adjusted life years gained vs semaglutide
    Study

    n: not reported in source

    Patient-level simulation model
    Comparator
    Semaglutide
    Outcome group
    Cost-effectiveness · Whole body
    Studied dose
    Maximum tolerated doseAs given in this study.

    Measurements

    QALYs gained
    0.506 QALY
    tirzepatide vs semaglutide

    Source sentences

    Summary
    Tirzepatide (MTD) was estimated to be less costly and more efficacious compared to semaglutide (MTD) with per patient cost savings of $41,688, 0.506 QALYs gained and positive iNHB of 0.784, indicating a net health benefit for tirzepatide.
    1 context sentence
    Summary · context
    This patient-level simulation modeling study assessed the cost and long-term clinical outcomes of tirzepatide (MTD) versus semaglutide (MTD), using data from the SURMOUNT-5 trial population.
  3. 03Computer modelIn silicoOther

    In a US simulation of adults with obesity or overweight, the incremental net health benefit of tirzepatide over semaglutide was positive.

    In plain wordsIn a computer simulation for obesity treatment, tirzepatide showed a net health benefit compared with semaglutide.

    Peptide
    Tirzepatide
    Outcome
    IncreaseIncremental net health benefit vs semaglutide
    Study

    n: not reported in source

    Patient-level simulation model
    Comparator
    Semaglutide
    Outcome group
    Cost-effectiveness · Whole body
    Studied dose
    Maximum tolerated doseAs given in this study.

    Measurements

    Incremental net health benefit
    0.784 QALY
    tirzepatide vs semaglutide

    Source sentences

    Summary
    Tirzepatide (MTD) was estimated to be less costly and more efficacious compared to semaglutide (MTD) with per patient cost savings of $41,688, 0.506 QALYs gained and positive iNHB of 0.784, indicating a net health benefit for tirzepatide.
    1 context sentence
    Summary · context
    This patient-level simulation modeling study assessed the cost and long-term clinical outcomes of tirzepatide (MTD) versus semaglutide (MTD), using data from the SURMOUNT-5 trial population.
  4. 04Computer modelIn silicoEfficacy outcome

    A simulation model predicted 70 fewer patients per 1,000 would develop type 2 diabetes with tirzepatide than with semaglutide.

    In plain wordsA computer simulation predicted fewer new cases of type 2 diabetes with tirzepatide than with semaglutide.

    Peptide
    Tirzepatide
    Outcome
    DecreasePredicted new type 2 diabetes cases
    Study

    n: not reported in source

    Patient-level simulation model
    Comparator
    Semaglutide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Maximum tolerated doseAs given in this study.

    Measurements

    Fewer patients developing T2D per 1,000
    70 patients
    tirzepatide vs semaglutide

    Source sentences

    Summary
    The model predicted that per 1,000 patients, 70 fewer patients will develop T2D
    1 context sentence
    Summary · context
    This patient-level simulation modeling study assessed the cost and long-term clinical outcomes of tirzepatide (MTD) versus semaglutide (MTD), using data from the SURMOUNT-5 trial population.
  5. 05Computer modelIn silicoEfficacy outcome

    A simulation model predicted 10 fewer patients per 1,000 would develop cardiovascular disease with tirzepatide than with semaglutide.

    In plain wordsA computer simulation predicted fewer new cases of heart and vessel disease with tirzepatide than with semaglutide.

    Peptide
    Tirzepatide
    Outcome
    DecreasePredicted new cardiovascular disease cases
    Study

    n: not reported in source

    Patient-level simulation model
    Comparator
    Semaglutide
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Maximum tolerated doseAs given in this study.

    Measurements

    Fewer patients developing CVD per 1,000
    10 patients
    tirzepatide vs semaglutide

    Source sentences

    Summary
    The model predicted that per 1,000 patients, 70 fewer patients will develop T2D, 10 fewer will develop CVD with tirzepatide (MTD)
    1 context sentence
    Summary · context
    This patient-level simulation modeling study assessed the cost and long-term clinical outcomes of tirzepatide (MTD) versus semaglutide (MTD), using data from the SURMOUNT-5 trial population.
  6. 06Computer modelIn silicoEfficacy outcome

    A simulation model predicted 3.07 more years living with moderate or severe obstructive sleep apnea with semaglutide than with tirzepatide.

    In plain wordsA computer model predicted more years with moderate or severe sleep apnea with semaglutide than with tirzepatide.

    Peptide
    Semaglutide
    Outcome
    IncreasePredicted years with moderate or severe obstructive sleep apnea
    Study

    n: not reported in source

    Patient-level simulation model
    Comparator
    Tirzepatide
    Outcome group
    Sleep · Respiratory
    Studied dose
    Maximum tolerated doseAs given in this study.

    Measurements

    Additional years with moderate/severe OSA
    3.07 years
    semaglutide vs tirzepatide

    Source sentences

    Summary
    patients spend 3.07 more years living with moderate/severe OSA when treated with semaglutide (MTD).
    1 context sentence
    Summary · context
    This patient-level simulation modeling study assessed the cost and long-term clinical outcomes of tirzepatide (MTD) versus semaglutide (MTD), using data from the SURMOUNT-5 trial population.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:07 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.